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Abstract
Breast cancer is the most frequently diagnosed cancer among women in the United States
and MDD is the most common mental health problem in women with breast cancer. There is
lack of research on measures of depression in this population. This study examined the
psychometric properties of three commonly used depression measures, the BDI-II, CES-D, and
HRSD, with clinically depressed breast cancer patients (n = 127). Findings revealed the
measures displayed good distributional characteristics, internal consistency, and convergent
validity. Discriminative validity with the BAI was not demonstrated, however, and confirmatory
factor analyses indicated that the existing models of these measures are inadequate. The results
indicate that these measures are appropriate for use with clinically depressed breast cancer
patients, but that further investigation of discriminative validity is necessary to better determine
construct validity with anxiety measures. Because of inadequate fit of this sample with existing
models, interpretation of scores on these measures may be better accomplished via reference to
more valid structural models obtained through exploratory factor analyses, providing a more
accurate conceptualization of the dimensions of MDD in breast cancer patients.
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Chapter 1
Introduction
Breast cancer is the most frequently diagnosed cancer among women in the United States
and second to only lung and bronchial cancer in mortality rates (Center for Disease Control and
Prevention: National Program of Cancer Registries, 2014). Functional difficulties during and
following treatment can include neurological impairment in the form of executive functioning,
attention, and memory deficits (Kessler, Kent, & O’Hara, 2011; McDonald, Conroy, Ahles,
West, & Saykin, 2012), poorer quality of life, decreased vitality, and social impairment (Hopko
et al., 2008), physical inactivity increasing risk for cardiovascular disease (Elme et al., 2013),
increased bodily pain and muscle rigidity (Hopko et al., 2008; Siegal et al., 2012), as well as
fatigue, insomnia, depression, and anxiety (Kim et al., 2008; Hall, Mishel, & Germino, 2014).
Indeed, women diagnosed with breast cancer are particularly vulnerable to depression and
anxiety in the first year following diagnosis (Burgess et al., 2005; Hopwood, Sumo, Mills,
Haviland, & Bliss, 2010; Reyes-Gibby, Anderson, Morrow, Shete, & Hassan, 2012). Relative to
non-depressed patients, depressed breast cancer patients have increased functional impairment in
terms of decreased quality of life, increased anxiety and substance use, impaired sexual
functioning, sleep disorders, decreased immune system functioning, more rapid progression of
cancer, more pain and fatigue, and possibly increased mortality (Deshields, Tibbs, Fan, &
Taylor, 2006; Hopko, McIndoo, Gawrysiak, & Grassetti, 2014; Reich, Lesur, & PerdrizetChevallier, 2008; Somerset, Stout, Miller, & Musselman, 2004; Spiegel & Giese-Davis, 2003).
A recent meta-analysis indicated depression is fairly common in cancer patients, with
prevalence ranging from 8-24% based on differential methods of assessment, type of cancer, and
phase of cancer treatment (Krebber et al., 2014). Specific to breast cancer, major depressive
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disorder (MDD) is the most common mental health problem, with a prevalence rate of 15-25%
(Fann et al., 2008; Hopko et al., 2014; Massie, 2004), with some suggesting up to 50% of women
with breast cancer experience debilitating depression (Hong, Tian, & Wu, 2014; Sachs et al.,
1995). Determining the precise prevalence and incidence of MDD in breast cancer patients has
proven challenging due to heterogeneity among patients, overlap of depressive and medical
symptoms, differing operational definitions and methods of assessing depression, and small, nonrepresentative samples in several studies. Perhaps most problematically, the psychometric
properties of self-report and clinician-rated depression measures are highly understudied among
breast cancer patients with well-diagnosed MDD as assessed via structured diagnostic interviews
(Fann et al., 2008; Hopko et al., 2014). Accordingly, the primary aim of this study was to
examine the psychometric properties of three commonly used measures of depression in breast
cancer patients with MDD: the Beck Depression Inventory (BDI-II; Beck et al., 1996), Center
for Epidemiologic Studies Depression Scale (CES-D; Radloff, 1977), and Hamilton Rating Scale
for Depression (HRSD; Hamilton, 1960).
The psychometric properties of the BDI-II have been studied extensively among various
samples of younger and older adults, adolescents, college students, primary care patients, and
psychiatric outpatients (Arnau, Meagher, Norris, & Bramson, 2001; Beck et al., 1996; Dozois,
Dobson, & Ahnberg, 1998; Huang & Chen, 2014; Osman et al., 1997; Segal, Coolidge, Cahill, &
O’Riley, 2008; Steer, Ball, Ranieri, & Beck, 1999; Steer & Clark, 1997; Steer, Kumar, Ranieri,
&Beck, 1998). The BDI-II is considered a highly valid and reliable measure of depression
(Huang & Chen, 2014; Nezu et al., 2001) and with few exceptions (Seignourel, Green, &
Schmitz, 2008; Vanheule, Desmet, Groenvynck, Rosseel, & Fontaine, 2008; Whisman, Judd,
Whiteford, & Gelhorn, 2013) consistently yields a two factor solution: somatic-affective and
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cognitive (Arnau et al., 2001, Huang & Chen, 2014; Steer et al., 1998). The CES-D is also well
studied among adults, adolescents, college students, and primary care patients, (Devins et al.,
1988; Hann, Winter, Jacobsen, 1999; Knight, Williams, McGee, Olaman, 1997; Verhoeven,
Sawyer, & Spence, 2013). The CES-D has good reliability and construct validity and although
alternative factor structures have been reported (Carleton et al., 2013), a four-factor model
consistently has been identified: depressive affect, absence of positive affect or anhedonia,
somatic symptoms, and interpersonal problems and challenges (Shafer, 2006). The HRSD is
commonly used to assess depression (Nezu et al., 2001; Steer, Beck, Riskind, & Brown, 1987)
and a recent meta-analysis on its psychometric properties revealed the HRSD generally has good
internal consistency, inter-rater, and test-retest reliability (Trajković et al., 2011). Although both
two- (depression, neurovegetative: Bech, Fava, Trivedi, Wisniewski, & Rush, 2011) and threefactor solutions (depression severity, insomnia, psychomotor behavior) have been proposed
(Hamilton, 1960, 1967), several studies identify a four-factor solution: depression, anxiety,
insomnia, and somatic components (Pancheri, Picardi, Pasquini, Gaetano, & Biondi, 2002;
Shafer, 2006). In summary, the BDI-II, CES-D, and HRSD are frequently used measures of
depression with very good psychometric properties across multiple samples and studies.
Assessing depression in breast cancer patients has involved utilization of several selfreport instruments. For example, the Hospital Anxiety and Depression Scale (HADS; Zigmond
& Snaith, 1983) was used to screen for depression in patients with operable breast cancer within
one year of cancer diagnosis and was a sensitive indicator of mood disorders in women under the
age of 50 (Ramirez, Richards, Jarrett, & Fentiman, 1995). However, the majority of studies
utilizing the HADS have revealed questionable psychometric properties including poor
reliability, discriminant validity, predictive validity, and sensitivity toward identifying mood
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disorders in breast cancer patients (Berard et al., 1998; Costantini et al., 1999; Hall, A’hern, &
Fallowfield, 1999; Love, Grabsch, Clark, Bloch, Kissane, 2004; Love, Kissane, Bloch, & Clark,
2002; Ramirez et al., 1995). In one large study that included breast cancer patients from
outpatient oncology clinics (Berard, Boermeester, & Viljoen, 1998), the HADS and Beck
Depression Inventory (BDI: Beck, Ward, Mendelson, Mock, & Erbaugh, 1968) were used to
screen for depression. Approximately 22% of participants also completed a structured diagnostic
interview and the overall prevalence of MDD was estimated at 14%. Results indicated the HADS
depression subscale and BDI collectively allowed for maximum sensitivity with optimal cutpoints specified (HADS: 8; BDI: 16). Another study of head and neck cancer patients examined
the sensitivity, specificity, and positive predictive values of the BDI-II, CES-D, HADS, and
HRSD in screening for MDD (Katz, Kopek, Waldron, Devins, & Tomlinson, 2004). The
prevalence of MDD was 20% and all measures had strong convergent and predictive validity.
A study including a sample of newly diagnosed patients with various cancer types used
the CES-D to assess depression prevalence, indicating the CES-D had strong internal consistency
(α = .87) and a depression prevalence rate of 40% based on a cut-point of 16 (Beeber, Shea, &
McCorkle, 1998). Pasacreta (1997) used the Diagnostic Interview Schedule (DIS; Robins,
Helzer, Croughnan, Williams, & Spitzer, 1987) and CES-D with women less then seven months
following their breast cancer diagnosis and reported 9% met criteria for MDD and 24% showed
elevated depressive symptoms. Pasacreta (1997) concluded the CES-D had limited predictive
power, however a more recent study demonstrated the CES-D (as well as BDI-II and HRSD) had
strong internal consistency and high sensitivity and specificity in distinguishing depressed and
non-depressed patients with various cancer types (Hopko et al., 2007). Finally, there are very
limited data suggesting the Patient Health Questionnaire-9 depression module (PHQ-9; Spitzer,
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Kroenke, &Willams, 1999) distress and impact thermometers (Akizuki, Yamawaki, Akechi,
Nakano, & Uchitomi, 2005; Holland, 1999), and other abbreviated assessment methods may be
reliable and valid measures of depression in medical samples including individuals with breast
cancer (Gil, Grassi, Travado, Tomamichel, & Gonzalez, 2005; Mitchell, 2007; Hegel et al.,
2008; Kroenke, Spitzer, & Williams, 2001).
The BDI-II, CES-D, and HRSD are three of the most widely used depression measures
and there are many significant reasons for investigating their psychometric properties. These
reasons include the need to examine construct validity through comparing depression symptom
factors across different depression measures, determining the equivalence of factor structures
across samples or groups (e.g., gender, ethnicity, age, or medical diagnoses), assessing
differential depression severity across patient samples, determining whether specific depression
symptom factors within a measure correlate differentially with external variables, and evaluating
the practicality and empirical value of using these depression measures in the assessment and
intervention process among patients with varying demographic, psychological, and medical
characteristics (Shafer, 2006). Accordingly, in the context of a paucity of research exploring
psychometric properties of depression measures in breast cancer patients with MDD and
considering how frequently these instruments are used with this population, systematic
evaluation of factor structures, internal consistency, and convergent and discriminant validity of
depression measures has major theoretical and clinical implications. Considering the prevalence
and impact of depression in breast cancer patients, examining psychometric properties of
potentially valuable depression screening measures is a pressing need.
This study investigated the properties of three depression measures in a sample of breast
cancer patients with MDD as diagnosed via structured clinical interviews. Primary hypotheses
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were as follows: (a) descriptive data would reveal normatively distributed data (i.e., skewness
and kurtosis); (b) descriptive data would resemble that reported in other clinical samples of
MDD patients and exceed that of non-clinical samples; (c) the BDI-II, CES-D, and HRSD would
be associated with high internal consistency; (d) strong convergent validity would be
demonstrated via high correlations across depression measures and MDD severity as assessed
through structured diagnostic interviews; and (e) discriminant validity would be demonstrated
with relatively lower correlations with a commonly used measure of anxiety (i.e., Beck Anxiety
Inventory: Beck & Steer, 1993). Finally, as this was the pioneering study of factor structures of
these measures in breast cancer patients with MDD, both confirmatory and exploratory factor
analyses were conducted to examine similarities to existing structural models.
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Chapter 2
Method
Participants
Participants included 127 female breast cancer patients recruited at the University of
Tennessee Medical Center Cancer Institute. Participants were included from treatment outcome
studies examining the efficacy of behavioral activation treatments for breast cancer patients with
MDD (Hopko et al., 2005, 2008, 2011) and were recruited by advanced clinical psychology
doctoral students or referred by treating oncologists. The principal investigator of the three
studies (DH) supervised all doctoral students. Participants were eligible if they were above 18
years of age, had been diagnosed with breast cancer, and had a principal (and primary) diagnosis
of MDD of moderate severity [i.e., at least “4” on a 0 (no depressive symptoms) to 8 (very
severe symptoms) scale]. Depending on the study, MDD was diagnosed using either the
Structured Clinical Interview for DSM-IV (SCID-I; First, Spitzer, Gibbon, & Williams, 1996) or
the Anxiety Disorders Interview Schedule-IV (ADIS-IV; Brown, DiNardo, & Barlow, 1994).
Participants ranged in age from 38 to 78 years [M = 54.9 years (SD = 11.7)]. The
majority of participants were Caucasian (95.3%; 4.7% African American). Marital status was as
follows: Married (56.7%), Single (25.2%), Divorced (15%), and Separated (3.1%). The
participants averaged 14.4 years of education (SD = 2.7). Approximately 42% of the sample was
employed either full or part-time, and remaining patients were unemployed (28%) or retired
(30%). Cancer data were gathered from pathology reports at the University of Tennessee
Medical Center’s Cancer Institute. The average length of time since cancer diagnosis was 2.8
years (SD = 3.8), and 78.7% of patients had infiltrating ductal carcinoma (IDC), 11% ductal
carcinoma in situ (DCIS), and 10.3% lobular carcinoma in situ (LCIS). The sample included
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patients of all cancer stages (Stage 0: 22%; Stage 1: 33.9%; Stage 2; 30.7%; Stage 3; 11.8%;
Stage 4; 1.6%). A total of 75% tested positive for estrogen receptor status, 65% for positive
progesterone receptor status, and 16% for the HER-2/NEU gene. In terms of cancer treatment,
94% of patients had surgery (i.e., lumpectomy, mastectomy), 74% had chemotherapy, 60% had
radiation treatment, and 1% had hormonal therapy. Participants were included if not taking
antidepressant or anti-anxiety medication (48%), or if they were taking such medications, had
been stabilized at a consistent dosage for 8 weeks prior to study assessment (48%). Due to
ethical considerations with regard to withholding treatment, patients also were included who had
initiated taking medication but were not stabilized (4%). A total of 10% reported having been
hospitalized for depression and 3% for another psychiatric problem. Mean level of ADIS-IV or
SCID-I clinician-rated severity of MDD was 5.3 (SD = 1.1), suggesting moderate clinical
depression. Coexistent diagnoses included GAD (n = 39; 30.7%), PTSD (n = 6; 4.7%), Social
Phobia (n = 12; 9.3%), Panic Disorder (n = 4; 3.1%), Anxiety NOS (n = 4; 3.1%), Specific
Phobia (n = 3; 2.4%), Dysthymia (n = 2; 1.6%), and OCD (n = 1; 0.8%).
Assessment Measures
The Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV; Brown et al., 1994) is
a semi-structured interview used as a diagnostic assessment for anxiety, mood, somatoform,
substance abuse and psychotic disorders. Disorders are separated into distinct modules and
symptoms are rated on a nominal scale and given ratings based on a continuum of severity and
interference. The ADIS-IV has excellent reliability and validity (Brown, DiNardo, Lehman, &
Campbell, 2001).
The Structured Clinical Interview for DSM-IV (SCID-I; First, Spitzer, Gibbon, &
Williams, 1996) is a semi-structured interview used to diagnose Axis I disorders based on DSM-
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IV criteria. The SCID is separated into modules according to diagnosis. Symptoms for each
diagnosis are categorized as present, sub-threshold, or absent. The inter-rater reliability of the
SCID-I ranges from good to excellent depending on the sample and diagnostic module
(Lobbestael, Leurgans, & Arntz, 2011; Löwe et al., 2004).
The Beck Depression Inventory-II (BDI-II; Beck et al. 1996) consists of 21 items rated on
a 4-point Likert scale. The instrument has excellent reliability and validity data with depressed
younger and older adults (Beck et al., 1996; Dozois, Dobson, & Ahnberg, 1998; Nezu, Ronan,
Meadows, & McClure, 2001). The psychometric properties of the BDI-II have been studied in
cancer patients and a diverse primary care sample, with the instrument having strong predictive
validity as it pertains to a diagnosis of MDD, strong internal consistency (α = .94), and adequate
item-total correlations (Arnau, Meagher, Norris, & Bramson; 2001; Hopko et al., 2007; Katz,
Kopek, Waldron, Devins, & Thomlinson, 2004).
The Center for Epidemiologic Studies Depression Scale (CES-D: Radloff, 1977) contains
20 items selected from previously validated scales of depression. It includes six components:
depressed mood; feelings of guilt and worthlessness; feelings of helplessness and hopelessness;
psychomotor retardation; loss of appetite; and sleep disturbance. Reliability and validity of the
CES-D have been tested in general and clinical populations, yielding very good internal
consistency [α = .85 for the general population and 0.90 for a psychiatric population].
Satisfactory test-retest reliability over a 2- to 8-week period ranged from 0.51 to 0.67 and from
0.32 to 0.54 over a 3- to 12-month period. The CES-D has moderate convergent validity with the
HRSD (r = 0.65) (Craig, Richardson, Pass, & Bregman, 1985).
The Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) is a 17-item semistructured interview designed to measure symptom severity in depressed patients. The instrument
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is the most widely used outcome measure for evaluating depression and is a standard outcome
measure in clinical trials (Kobak & Reynolds, 1999; Wolf & Hopko, 2008).
The Beck Anxiety Inventory (BAI; Beck, Epstein, Brown, & Steer, 1988) is a 21-item
measure designed to distinguish cognitive and somatic symptoms of anxiety from those of
depression. Good psychometric properties have been demonstrated among community, medical,
and psychiatric outpatient samples (Antony, Orsillo, & Roemer, 2001; Morin et al., 1999;
Wetherell & Areán, 1997).
Procedure
All participants were administered either the SCID or ADIS-IV by an advanced clinical
psychology doctoral student trained by the principal investigator (DH). Those patients who were
diagnosed with MDD then completed the BDI-II, BAI, CES-D, and HRSD. The original studies
(Hopko et al., 2005, 2008, 2011) included several assessment intervals (i.e., pre-treatment, posttreatment, 3-month, 6-month, 9-month, and 12-month follow-ups). All data used for the
following analyses were from the pre-treatment assessments of all patients. All assessments were
completed at the University of Tennessee Medical Center Cancer Institute.
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Chapter 3
Results
Descriptive Data and Internal Consistency
Tests of multivariate normality were used to examine distributional characteristics of data
for each depression measure (n = 127). For the BDI-II (M = 26.32, SD = 10.27: α = .90), both the
symmetry (skewness = .72, SE = .22) and “flatness” (kurtosis = .33, SE = .43) of the distribution
were within acceptable limits (Hair et al., 1995). In addition, a powerful test of normality for
sample sizes over 100 (Razali & Wah, 2007), the Kolmogorov-Smirnov (KS) statistic suggested
sample data were normally distributed (KS = .08, p = .06). Significantly increased depression
was observed relative to a large non-clinical sample [(M = 8.36, SD = 7.16); t (152) = 18.77, p <
.01; Whisman, Perez, & Ramel, 2000]. The BDI-II scores did not significantly differ from a
sample of clinically depressed outpatients [(M = 28.64, SD = 11.75); t (293) = -1.90, p = .06;
Steer, Ball, Ranieri, & Beck, 1999], but was significantly lower than a recent treatment-seeking
sample of depressed patients [(M = 32.0, SD = 7.5); t (198) = -5.52, p < .01; Dimidjian et al.,
2006]. The current sample of depressed breast cancer patients did report significantly greater
depression relative to three groups of cancer patients including patients receiving antineoplastic
and supportive treatments [(M = 15.47, SD = 8.36); t (151) = 7.83, p < .01; O’Mahony et al.,
2005], women receiving chemotherapy for early stage breast cancer [(M = 11.10, SD = 6.55); t
(139) = 11.71, p < .01; Bower et al., 2011], and breast cancer patients following treatment (i.e.,
chemotherapy, radiation, surgery) [(M = 7.34, SD = 7.58); t (130) = 13.72, p < .01; Bower et al.,
2011]. For this study sample, internal consistency of the BDI-II was strong (α = .90).
For the CES-D (M = 30.56, SD = 10.05: α = .85), both the skewness (-.12, SE = .22) and
kurtosis (-.49, SE = .43) were within acceptable limits and data were normally distributed (KS =

12
.06, p = .20). Internal consistency of the CES-D was strong (α = .85). Significantly greater
depression was reported on the CES-D in this sample relative to a large non-clinical community
sample [(M = 5.02, SD = 7.23); t (161) = 26.86, p < .01; Boyd, Weissman, Thompson, & Myers,
1982], a sample of depressed cancer patients [(M = 23.6, SD = 7.02); t (120) = 5.16, p < .01;
Bodurka-Bevers et al., 2000], and several medical samples including a non-cancerous medical
group [(M = 8.3, SD = 6.4); t (185) = 22.59, p < .01; Van Wilgen, Dijkstra, Stewart, Ranchor, &
Roodenburg, 2006], and two samples of breast cancer patients [(M = 10.5, SD = 8.3); t (234) =
18.63, p < .01; Van Wilgen et al., 2006]; [(M = 11.53, SD = 9.01); t (221) = 14.77, p < .01;
Antoni et al., 2001].
Finally, for the HRSD (M = 14.31, SD = 6.11: α = .75), sample data also were normally
distributed [skewness (.35, SE = .22); kurtosis (-.40, SE = .43); KS = .07, p = .20]. Internal
consistency of the HRSD for the current sample was acceptable (α = .75). Because the HRSD is
a clinician-rated measure for individuals with MDD, there were no non-clinical samples to
compare to the present sample. Clinician-rated depression on the HRSD was significantly lower
than two large sample of depressed patients [(M = 20.7, SD = 4.2); t (187) = -10.65, p < .01;
Dimidjian et al., 2006] [(M = 19.5, SD = 4.4); t (197) = -8.48, p < .01; Elkin et al., 1989] but was
comparable to heterogeneous samples of patients with cancer across many sites and stages
[Sample 1: (M = 16.02, SD = 7.28); t (88) = -1.53, p = .13; Sample 2: (M = 14.31, SD = 8.12); t
(91) = -0.06, p = .95; Foley, Baillie, Huxter, Price, & Sinclair, 2010].
Convergent and Discriminant Validity
Convergent validity was assessed based on Pearson Product-Moment correlations among
depression measures and MDD depression severity as measured by a structured clinical
interview. As presented in Table 1, strong convergent validity was evident between the BDI-II
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and CES-D. Convergent validity was more moderate between the HRSD and both the BDI-II and
CES-D. All three measures exhibited moderate convergent validity with depression severity as
assessed via structured diagnostic interviews. Discriminant validity was examined through
correlations between depression measures and the BAI. Based on a series of non-significant
Pearson’s tests of dependent correlations, there was minimal evidence to support discriminative
validity in terms of the BAI correlating significantly less with depression measures relative to the
inter-correlations among depression measures. In fact, only the relationship of the BDI-II and
CES-D (r = .72) compared to the BDI-II and BAI (r = .63) approached statistical significance (z
=1.60, p = .06).
Confirmatory Factor Analyses
Confirmatory factor analyses (CFA) were used to examine the adequacy of existing
structural models for the BDI-II, CES-D, and HRSD as applied to data obtained from the current
sample of female breast cancer patients diagnosed with MDD. All statistics were computed using
SPSS Amos for structural equation modeling (Arbuckle, 2006). As per recommendations in
reporting results of CFA (Thompson & Daniel, 1996), the Root Mean Square Error of
Approximation (RMSEA), chi-square, and the Bentler’s comparative (BCFI), goodness-of-fit
(GFI), adjusted goodness of fit (AGFI), and normed fit (NFI) indexes are presented.
Contemporary goodness-of-fit criteria were used whereby an RMSEA of .06 and a CFI (and
GFI) value of .95 were required for conclusions to be drawn that a good fit existed between the
hypothesized model and observed data (Browne & Cudeck, 1992; Hu & Bentler, 1998). The χ2/
df values were expected to be as low as 2 and as high as 5 to indicate a value within the range of
reasonable fit (Marsh & Hocevar, 1985).
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Hypothesized Models
As outlined in the introduction, the BDI-II was assessed using both two- and three-factor
models, as well as one hierarchical four-factor measurement model. The two-factor models
included somatic-affective and cognitive subscales (Steer et al., 1998; Arnau et al., 2001; Huang
& Chen, 2014). The two three-factor models included somatic, affective, and cognitive factors
(Seignourel, Green, & Schmitz, 2008; Vanheule, Desmet, Groenvynck, Rosseel, & Fontaine,
2008). The hierarchical four-factor measurement model was made of three first-order factors
(negative attitude, performance difficulty, somatic elements) and one second order factor
(depression) (Whisman, Judd, Whiteford, & Gelhorn, 2013).
The CES-D was compared to a both three and four-factor models. The three-factor model
consisted of negative affect, anhedonia, and somatic symptoms subscales (Carleton et al., 2013).
The four-factor model included somatic, depressed affect, positive affect, and interpersonal
problems subscales (Shafer, 2006). Finally, the HRSD was examined using a one-factor model
(depression; Bech, Fava, Trivedi, Wisniewski, & Rush, 2011) and several four-factor models.
One model consisted of a somatic anxiety/somatization, psychic anxiety, pure depression, and
anorexia subscales (Pancheri, Picardi, Pasquini, Gaetano, & Biondi, 2002). The original
Hamilton (1960) article and subsequent study (1967) both discuss four-factor models, but all of
the subscales are not clearly labeled. Some factor labels from those models include retarded
depression, agitated depression, anxiety reaction, general depression, and retarded vs. agitated
depression. The final model examined consisted of anxiety, depression, insomnia, and somatic
subscales and was the closet to being considered an appropriate fit with this sample’s data
(Shafer, 2006). As highlighted in Table 2, data from the current patient sample generally was a
poor fit with previously established factor structures for all three depression measures.
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Exploratory Factor Analyses
Following the CFA findings, exploratory factor analyses (EFA) were performed on the
BDI-II, CES-D, and HRSD to investigate alternative factor structures. For each EFA, a principal
components extraction and varimax rotation method was used with the number of factors
initially unspecified. An orthogonal varimax rotation was chosen to allow for clarification of
uncorrelated factors within each measure. The factor loadings and related interpretability (i.e.,
face validity of items), scree-plot analysis (Cattell, 1966), and factor eigenvalues as assessed
using parallel analysis procedures (Glorfeld, 1995; Watkins, 2000) were employed to determine
optimal factor structure of the three depression measures.
BDI-II. An EFA was first performed on the BDI-II items with the number of factors
unspecified for the model. Factor eigenvalues were then assessed using parallel analysis. A twofactor model was found to be most parsimonious for the data. A second EFA was then performed
specifying a two-factor model. The two factors accounted for 43% of the variance in
participants’ responses (Factor 1 = 34%, eigenvalue = 7.17; Factor 2 = 9%, eigenvalue = 1.81).
The two-factor solution is presented in Table 3. To load significantly on a factor, an item had to
have a factor loading greater then or equal to .40, with the loading on the alternative factor(s)
being greater then or equal to a .20 difference from the primary factor (Hair, Anderson, Tatham,
& Black, 1995). Given the nature of the nine items loading onto factor 1, it was labeled Negative
Attitudes Toward Self, while the nine items loading onto factor 2 were labeled SomaticAffective. The agitation, indecisiveness, and concentration difficulty items did not load
significantly or discriminantly onto either of the two factors.
CES-D. An initial EFA with the number of factors unspecified was performed on the
CES-D. Following examination of results of the first EFA and using parallel analysis procedures
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to determine optimal factor structure, the second EFA was performed with three factors
specified. The three factors accounted for 49% of the variance in participants’ responses (Factor
1 = 28%, eigenvalue = 5.56; Factor 2 = 12%, eigenvalue = 2.39; Factor 3 = 9%, eigenvalue =
1.70). The three-factor solution is displayed in Table 4. Items were designated as significant
loadings based on the algorithm described above. The items loading significantly onto factor 1
were almost identical to two of Radloff’s (1977) original factors, the Somatic and Retarded
Activity factor and Depressed Affect factor. Factor 1 was labeled Somatic-Depressed Affect. The
items that loaded onto factor 2 were three of the four items included in Radloff’s Positive Affect
factor, and therefore factor 2 was given the same label. Finally, factor 3 consisted of both items
in Radloff’s original Interpersonal Problems factor, and two additional items. Because the
additional two items, “I felt that I was just as good as other people” and “I thought my life had
been a failure,” could be interpreted as interpersonal comparisons, factor 3 was labeled
Interpersonal. On the CES-D, only items 7 and 20 did not load significantly on any of the three
factors.
HRSD. As with the two self-report measures, results from an initial EFA with unspecified
factors and parallel analyses indicated a three-factor model was most parsimonious with data
obtained on the HRSD. A second EFA was then performed specifying three factors. The three
factors accounted for 40% of the variance (Factor 1 = 22%, eigenvalue = 3.73; Factor 2 = 9%,
eigenvalue = 1.61; Factor 3 = 9%, eigenvalue = 1.47). The three-factor solution is presented in
Table 5. Using the item designation procedure highlighted above, unlike the BDI-II and CES-D,
which more concisely mapped onto empirically derived factor structures, the HRSD factors were
not as clearly defined. Due to the nature of the six items loading significantly onto factor 1, it
was labeled Somatic Anxiety. The five items loading onto factor 2 were all symptoms of
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depression, so factor 2 was labeled Depressive Affect. Three of the four items loading onto
factor 3 were insomnia and the fourth assessed weight loss, resulting in this factor being labeled
Neurovegetative. Although somewhat less clearly defined than the BDI-II and CES-D factors,
HRSD factors reveal high face and content validity with the construct of depression.
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Chapter 4
Discussion
The primary aim of this study was to investigate the psychometric properties and factor
structures of three common measures of depression to evaluate their appropriateness for use with
depressed breast cancer patients. Following tests of data normality, internal consistency as well
as convergent and discriminant validity of the three measures were assessed. Confirmatory factor
analyses investigated the fit of sample data with several existing factor structures for each
depression measure and exploratory factor analyses provided additional information about the
underlying factor structure of the data. For all three depression measures, tests of multivariate
normality revealed that distribution scores were within acceptable limits, indicating sample data
were normally distributed. Internal consistency of both the BDI-II and CES-D were strong, with
the HRSD having lower but adequate internal consistency. Good convergent validity also was
evident in the relationships of all three depression measures as well as their associations with
severity of MDD as assessed by structured diagnostic interviews. It is conceivable that the more
moderate convergent validity between the BDI-II and the HRSD was an administration artifact
(i.e., self-report versus clinician-rated). Discriminant validity with a measure of somatic anxiety
(BAI) was not demonstrated, suggesting that for depressed breast cancer patients it might be
difficult to discriminate between symptoms of depression, anxiety, and somatic complaints
potentially related to the diagnosis and treatment of breast cancer (Raison & Miller, 2003).
Pertaining to cross-sample descriptive comparisons, self-reported depression on the BDIII was significantly higher than a non-clinical sample as well as referenced samples of cancer
patients, and the data were equivocal in terms of comparisons with clinically depressed patients.
Similar to the BDI-II, self-reported depression on the CES-D was significantly higher than a
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non-clinical community sample. Relative to clinically depressed samples, CES-D rated
depression was lower in the current sample but higher when compared to several medical
samples that included depressed cancer patients. Clinician-rated depression on the HRSD was
significantly lower relative to clinically depressed samples, but largely consistent with studies of
cancer patients at different stages in cancer treatment, and regardless of whether cancer patients
were seeking treatment for depression. Collectively, these findings indicate breast cancer patients
with depression report significant psychological distress on common measures of depression.
For all three depression measures, confirmatory factor analyses of existing factor
structures did not fit well with current data. For the BDI-II, the closest fit to this sample was a
three-factor model including somatic, affective, and cognitive subscales (Vanheule, Desmet,
Groenvynck, Rosseel, & Fontaine, 2008). Nonetheless, even this model was rejected as all fit
indices were all outside acceptable ranges. A subsequent exploratory factor analyses revealed
that the BDI-II consisted of two-factors, labeled “Negative Attitudes Toward Self” and
“Somatic-Affective.” The “Somatic-Affective” factor is common among two-factor models
(Steer et al., 1998; Arnau et al., 2001; Huang & Chen, 2014) but the “Negative Attitudes
Towards Self” is not generally evident in two-factor structures. The “Negative Attitudes
Towards Self” factor does overlap with the “Negative Attitude” first-order factor in a recent
hierarchical model, however (Whisman, Judd, Whiteford, & Gelhorn, 2013), and is similar to the
“Negative Attitudes Towards Self” factor observed in the original BDI (Beck & Lester, 1973).
Sample data on the CES-D were subjected to both a three- and four-factor model of the
CES-D using confirmatory factor analyses, with the former model providing the closest fit, albeit
still unsatisfactory based on not meeting fit index criteria. A subsequent exploratory factor
analyses revealed a three-factor model consisting of “Somatic-Depressed Affect,” “Positive
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Affect,” and “Interpersonal” factors. Similar to self-report measures, confirmatory factor
analyses of the HRSD revealed inadequate fit for the one-factor model as well as several fourfactor models. Exploratory factor analyses revealed an underlying three-factor structure of the
HRSD, including “Somatic Anxiety, “Depressive Affect,” and “Neurovegetative” factors.
The present study yielded provocative findings in terms of the utility of three common
measures to assess depression in breast cancer patients. A few notable limitations include using a
reasonably large sample size, however, a larger sample size from several different recruitment
sites would strengthen study findings. Second, this sample consisted mainly of Caucasian
females, and although this demographic feature is representative of the area in which data were
collected, it reduces the generalizability of the results to other racial and ethnic groups. Third, the
majority of the sample was composed of patients diagnosed with Stage 0-2 breast cancer, with
only 13% of the sample diagnosed with Stage 3 or 4 breast cancer. Although it is understandable
that patients with more severe cancer and (possibly) more invasive cancer treatment would be
less likely to have the energy and motivation to participate in treatment outcome studies, it will
be important to address this issue in future research to better understand whether depression
measures are appropriate for use with breast cancer patients in all stages of cancer. Finally, as the
study sample included breast cancer patients from one medical center from largely rural areas, it
will be important to assess the generalizability of results to other medical centers and
geographical regions.
Although the study has some noteworthy limitations, it provides an important preliminary
investigation of three commonly used depression measures with a clinically depressed breast
cancer sample. A psychometric examination of this kind has not been done with both a clinically
depressed sample of breast cancer patients and thus adds to our knowledge of the appropriateness
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of measures toward assessing depression and cancer patients and medical populations in general.
Results of this study reveal several findings that support the notion that these measures are
suitable for use in depressed breast cancer patients, including good distributional characteristics,
adequate to strong internal consistency, and good convergent validity. However, further
investigation of the discriminative validity of these measures is necessary to better determine
construct validity relative to affective measures of anxiety. Given the medical sample studied,
perhaps using less somatic measures of anxiety such as the State-Trait Anxiety Inventory or Penn
State Worry Questionnaire might yield increased support for the discriminant validity of
depression measures. Finally, it was evident that existing factor structures of depression
measures were largely inadequate insofar as generalizing to this sample of cancer patients.
Accordingly, interpretation of scores on these measures may be better accomplished via
reference to more valid structural models obtained through exploratory factor analyses -providing a more accurate conceptualization of the dimensions of MDD in breast cancer patients.
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Table 1.
Correlations Among Depression and Anxiety Measures
1
2
3
4
5
1. BDI-II
.72
.58
.63
.60
2. CES-D
.58
.56
.58
3. HRSD
.56
.57
4. BAI
.35
5. SCID/ADIS
Note. All correlations are significant at the 0.001 level (2-tailed).
BDI-II = Beck Depression Inventory-II; CES-D = Center for Epidemiologic Studies Depression
Scale; HRSD = Hamilton Rating Scale for Depression; BAI = Beck Anxiety Inventory;
SCID/ADIS = Severity rating from structured clinical interview (ADIS-IV or SCID-I).
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Table 2.
Confirmatory Factor Analyses of Established Models
Citation
Factor CoRMSEA BCFI
Model variance
of
factors
BDI-II Steer et al., 2
Yes
.08
.87
1998
BDI-II Arnau,
2
Yes
.07
.85
Meagher,
Norris, &
Bramson,
2001
BDI-II

Huang &
Chen, 2014
BDI-II Seignourel,
Green, &
Schmitz,
2008
BDI-II Vanheule,
Desmet,
Groenvync
k, Rosseel,
& Fontaine,
2008
BDI-II Whisman,
Judd,
Whiteford,
& Gelhorn,
2013
CES-D Carleton et
al., 2013
CES-D Shafer,
2006
HRSD Bech, Fava,
Trivedi,
Wisniewski
, & Rush,
2011
HRSD Hamilton,
1960
HRSD Hamilton,
1967

GFI AGFI NFI

χ2/ df

p

.84

.79

.75

1.76

.00

.82

.78

.71

1.65

.00

2

Yes

.08

.84

.81

.76

.71

1.81

.00

3

Yes

.08

.82

.80

.75

.69

1.86

.00

3

Yes

.07

.89

.87

.83

.76

1.67

.00

Hierar 4
-chical

.08

.84

.81

.76

.71

1.75

.00

3

Yes

.07

.92

.87

.81

.81

1.59

.00

4

Yes

.08

.81

.79

.73

.68

1.87

.00

1

No

.08

.72

.84

.80

.53

1.72

.00

4

No

.10

.57

.80

.73

.44

2.13

.00

4

No

.09

.67

.89

.77

.54

1.99

.00
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Table 2. Continued
Citation

HRSD

Factor
Model

Covariance
of
factors

RMSEA BCFI

GFI AGFI NFI

χ2/ df

p

Pancheri,
4
Yes
.07
.81
.88 .83
.62
1.53
.00
Picardi,
Pasquini,
Gaetano, &
Biondi,
2002
HRSD Shafer,
4
Yes
.06
.85
.88 .83
.64
1.40
.00
2006
Note. BDI-II = Beck Depression Inventory-II; CES-D = Center for Epidemiologic Studies
Depression Scale; HRSD = Hamilton Rating Scale for Depression; BAI = Beck Anxiety
Inventory; RMSEA = Root Mean Square Error Approximation; CFI = Comparative Fit Index;
GFI = Goodness-of-Fit Index; AGFI = Adjusted Goodness-of-Fit Index; NFI = Normed Fit
Index; χ2 = Chi-square /df = Degrees of Freedom; p = p-value of χ2/ df.
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Table 3.
Varimax Rotated Factor Loadings of BDI-II Items
Factor Loading
Item
1
2
1. Sadness
.36
.59
2. Pessimism
.52
.26
3. Past Failure
.78
.19
4. Loss of Pleasure
.27
.61
5. Guilty Feelings
.81
.09
6. Punishment Feelings
.62
.18
7. Self-Dislike
.62
.30
8. Self-Criticalness
.82
.19
9. Suicidal Thought or Wishes
.47
.19
10. Crying
.25
.46
11. Agitation
.39*
.32*
12. Loss of Interest
.30
.59
13. Indecisiveness
.44•
.48•
14. Worthlessness
.67
.18
15. Loss of Energy
.18
.71
16. Changes in Sleep Pattern
.23
.44
17. Irritability
.54
.21
18. Changes in Appetite
.08
.68
19. Concentration Difficulty
.41•
.44•
20. Tiredness or Fatigue
.14
.73
21. Loss of Interest in Sex
.15*
.37*
Note. BDI-II = Beck Depression Inventory-II. Factor loadings in bold specify the designated
factor. * = Undesignated item. • = Item loads on to more than one factor. Factor 1 = Negative
Attitudes Toward Self. Factor 2 = Somatic-Affective.
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Table 4.
Varimax Rotated Factor Loadings of CES-D Items
Factor Loading
Item
1
2
3
1. Bothered by things
.60
.14
.14
2. Poor appetite
.51
.18
.31
3. Could not shake the blues
.73
.32
.09
4. Feel as good as others
.04
.14
.61
5. Couldn’t keep mind on tasks
.55
.04
.01
6. Felt depressed
.66•
.41•
.15
7. Everything an effort
.56•
.50•
.04
8. Hopeful about future
.08
.70
.05
9. Life is a failure
.26
.25
.68
10. Felt fearful
.58
.13
.34
11. Restless sleep
.59
.11
.08
12. Felt happy
.01
.80
.21
13. Talked less than usual
.47
.04
.20
14. Felt lonely
.60
.03
.27
15. People were unfriendly
.10
.10
.59
16. Enjoyed life
.05
.78
.18
17. Crying spells
.48
.17
.28
18. Felt sad
.68
.24
.23
19. People dislike me
.25
.01
.78
20. Could not get going
.56•
.46•
.13
Note. CES-D = Center for Epidemiologic Studies Depression Inventory Scale. Factor loadings in
bold specify the designated factor. • = Item loads on to more than one factor. Factor 1 =
Somatic-Depressed Affect. Factor 2 = Positive Affect. Factor 3 = Interpersonal.

46
Table 5.
Varimax Rotated Factor Loadings of HRSD Items
Factor Loading
Item
1
2
3
1. Depressed mood
.02
.66
.22
2. Guilt
.28
.50
.06
3. Suicide
.42
.05
.16
4. Insomnia initial
.03
.25
.46
5. Insomnia middle
.12
.25
.61
6. Insomnia delayed
.27
.12
.68
7. Work and interests
.19
.50
.30
8. Retardation
.20
.42
.18
9. Agitation
.12
.39*
.38*
10. Anxiety psychic
.53•
.53•
.04
11. Anxiety somatic
.70
.26
.02
12. Gastrointestinal
.59
.13
.38
13. General somatic
.71
.26
.01
14. Libido loss
.68
.20
.06
15. Hypochondriasis
.44
.24
.15
16. Weight loss
.14
.14
.63
17. Insight loss
.01
.40
.13
Note. HRSD = Hamilton Rating Scale for Depression. Factor loadings in bold specify the
designated factor. * = Undesignated item. • = Item loads on to more than one factor. Factor 1 =
Somatic Anxiety. Factor 2 = Depressive Affect. Factor 3 = Neurovegetative.
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